The SET oncoprotein participates in cancer progression by affecting multiple cellular processes, inhibiting the tumor suppressor protein phosphatase 2A (PP2A), and inhibiting the metastasis suppressor nm23-H1. On the basis of these multiple activities, we hypothesized that targeted inhibition of SET would have multiple discrete and measurable effects on cancer cells. Here, the effects of inhibiting SET oncoprotein function on intracellular signaling and proliferation of human cancer cell lines was investigated. We observed the effects of COG112, a novel SET interacting peptide, on PP2A activity, Akt signaling, nm23-H1 activity and cellular migration/ invasion in human U87 glioblastoma and MDA-MB-231 breast adenocarcinoma cancer cell lines. We found that COG112 interacted with SET protein and inhibited the association between SET and PP2A catalytic subunit (PP2A-c) and nm23-H1. The interaction between COG112 and SET caused PP2A phosphatase and nm23-H1 exonuclease activities to increase. COG112mediated increases in PP2A activity resulted in the inhibition of Akt signaling and cellular proliferation. Additionally, COG112 inhibited SET association with Ras-related C 3 botulinum toxin substrate 1 (Rac1), leading to decreased cellular migration and invasion. COG112 treatment releases the SET-mediated inhibition of the tumor suppressor PP2A, as well as the metastasis suppressor nm23-H1. These results establish SET as a novel molecular target and that the inhibition of SET may have beneficial effects in cancer chemotherapy.
Introduction
The protein encoded by the oncogene SET (TAF-1/ I 2 PP2A) has multiple cellular functions, including control of cell cycle (Canela et al., 2003; Carujo et al., 2006) , gene transcription (Compagnone et al., 2000) , apoptosis (Madeira et al., 2005) , cell migration (ten Klooster et al., 2007) and epigenetic regulation (Seo et al., 2001) . SET was discovered as the SET-CAN fusion gene associated with myeloid leukemogenesis (von Lindern et al., 1992; Adachi et al., 1994) . SET is highly expressed in Wilms' tumors (Carlson et al., 1998) and may contribute to liver carcinogenesis (Fukukawa et al., 2000) . Furthermore, SET expression is high in rapidly dividing cells, but low in quiescent or contactinhibited cells, indicating a potential selectivity for SET expression levels and cell growth potential (Carlson et al., 1998) . Taken together, SET has an important role in facilitating cellular growth and proliferation and interacts with pathways that promote tumorigenesis and metastasis.
SET contributes to tumorigenesis, in part, by forming an inhibitory protein complex with protein phosphatase 2A (PP2A) (Li et al., 1995 (Li et al., , 1996 . The tumor suppressor PP2A is a major cellular phosphatase that negatively regulates multiple pro-growth/pro-survival signaling pathways associated with cancer progression, such as Akt, b-catenin and c-Myc (Gotz et al., 2000; Resjo¨et al., 2002; Arnold and Sears, 2008) . These pathways are often dysregulated in cancers, and SET expression further exacerbates the effect of uncontrolled signaling by inhibiting the endogenous regulators of these pathways. Interestingly, expression of the SET-CAN fusion gene in mice correlates with overexpression of b-catenin in stomach mucosa and indicates a role in cellular proliferation for this oncogene (Ozbek et al., 2007) . As PP2A is the endogenous regulator of multiple pathways associated with cancer progression, the pharmacological activation of PP2A is a desirable goal for cancer chemoprevention and chemotherapy (Westermarck and Hahn, 2008; Eichhorn et al., 2009) . Although commonly repressed in cancer cells, PP2A activity can be pharmacologically manipulated (Feschenko et al., 2002; Guichard et al., 2006; Neviani et al., 2007; Perrotti and Neviani, 2008; Switzer et al., 2009) .
SET also forms an inhibitory complex with nm23-H1 (Fan et al., 2003) , a metastasis suppressor whose expression level is inversely related to the metastatic potential of a cancer cell (Steeg et al., 1988; Rosengard et al., 1989) . The metastasis suppressor, nm23-H1, is a multi-tasking protein with histidine kinase, nucleosidediphosphate kinase and 3 0 -5 0 exonuclease activities (Freije et al., 1998) . The DNA exonuclease activity of nm23-H1 is central to its metastasis suppressor function (Zhang et al., 2010) , which SET modulates by forming a complex that sequesters nm23-H1 into the cytosol, thereby preventing its exonuclease activity and promoting metastasis (Fan et al., 2003) . Upon attack by cytotoxic lymphocytes, SET is cleaved by Granzyme A, releasing nm23-H1 to translocate into the nucleus and exert its exonuclease activity (Fan et al., 2003) . Therefore, SET has a key role in numerous pathways that lead to more aggressive phenotypes and provides a unique opportunity to target multiple pathways involved in tumor progression.
Because of the diverse roles of SET in multiple pathways leading to cancer progression and metastasis, the pharmacological targeting of the SET oncoprotein could provide a novel approach to anti-cancer therapy. Recently COG112, a novel peptide based on a short fragment of apolipoprotein-E, was reported to bind to SET expressed in immune cells that led to an increase in PP2A activity (Christensen et al., 2011) . We report here that COG112 targets the oncoprotein functions of SET in human cancer cells and results in the dissociation of SET from PP2A, nm23-H1 and Ras-related C 3 botulinum toxin substrate 1 (Rac1). COG112 treatment also resulted in increased PP2A activity that corresponded to decreased Akt signaling and c-Myc stability. Furthermore, nm23-H1 translocated to the nucleus under conditions where cellular migration and invasion were inhibited by this novel peptide. In contrast to cancer cells, COG112 shows limited toxicity and good bioavailability in whole animals, primary cells in culture and various cell lines, making it an attractive candidate for anti-cancer therapy in humans (Li et al., 2006; Christensen et al., 2011) . The data presented here indicate that pharmacological targeting of the oncoprotein SET results in multiple beneficial effects in the potential treatment of human cancer.
Results

COG112 binds to SET protein
COG112 was recently reported to interact with SET protein in immune cells (Christensen et al., 2011) . To confirm that COG112 interacted with SET from MDA-MB-231 human breast adenocarcinoma cells, either biotin or biotin-labeled COG112 was incubated with whole-cell lysates and proteins bound to COG112 peptide were pulled down using streptavidin-conjugated agarose beads. Immunoprecipitated proteins were western blotted and probed with anti-SET antibodies to show a predominant 39-kDa SET protein band that was not present in biotin-only controls (Figure 1a ), suggesting a specific interaction between COG112 and the SET protein.
COG112 disrupts PP2A-c and SET association
To determine whether COG112 can specifically inhibit the PP2A catalytic subunit (PP2A-c) from forming a complex with SET, serum-starved MDA-MB-231 cells were treated with COG112 for 2 h before epithelial growth factor (EGF) stimulation. Co-immunoprecipitation studies show that COG112 caused a concentration-dependent decrease in SET bound to PP2A-c in EGF-stimulated cells (Figure 1b ), indicating that COG112 reduced the interaction of SET with PP2A-c. (a) COG112 interacts with SET. MDA-MB-231 whole-cell lysate was incubated with biotin or biotin-COG112. Proteins pulled down with streptavidin-agarose beads were immunoblotted with anti-SET/I 2 PP2A. (b) COG112 inhibits SET-PP2A-c association. MDA-MB-231 cells were incubated with COG112 for 2 h before EGF. SET and PP2A-c protein complexes were immunoprecipitated and analyzed for SET and PP2A-c co-precipitation. COG112 inhibited SET-PP2A-c complex formation in a concentrationdependent manner. (inset: SET-PP2A-c association in serumstarved cells treated with or without EGF). (c) COG112 increases PP2A activity. PP2A-c was immunoprecipitated from COG112treated U87 cells and phosphatase activity measured using a synthetic phospho-peptide. Data represent mean values ( ± s.e.m.) of released phosphate from three independent experiments. Significance (*Po0.05) is relative to EGF controls.
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COG112 increases PP2A phosphatase activity
To determine whether COG112 altered PP2A activity, MDA-MB-231 and U87 cells were treated as above and phosphatase activity was measured from immunoprecipitated PP2A-c, using a specific phospho-peptide substrate. The PP2A-c from untreated U87 cells had significantly higher phosphatase activity compared with EGF-stimulated cells (Figure 1c ). EGF-stimulated cells pretreated with COG112 (X10 nM) had significantly higher phosphatase activity than EGF-stimulated cells (Figure 1c ). Although COG112 pretreatment significantly increased PP2A phosphatase activity, it did not completely restore the activity to those measured in serum-starved untreated control cells.
COG112 inhibits Akt signaling through PP2A activation
Akt is a critical target in cancer therapy (LoPiccolo et al., 2007) and is negatively regulated by PP2A (Resjoë t al., 2002) . We investigated the effects of COG112 on Akt signaling in response to EGF stimulation of MDA-MB-231 and U87 cells. Cells were treated with COG112 in the presence or absence of okadaic acid (OA), an inhibitor of PP2A, for 2 h before stimulation with EGF. Akt activation, as measured by phospho-Akt (phosphoserine-473) levels, was concentration dependently inhibited by COG112 in the absence of OA, but had no effect on Akt activation in the presence of OA (Figure 2a ). Analysis of three independent experiments shows that 100 and 1000 nM COG112 significantly decreased Akt activation compared with COG112 and OA treatment ( Figure 2b ). Furthermore, COG112 did not alter proximal EGF signaling, as epithelial growth factor receptor (EGFR) and 3-phosphoinositide dependent protein kinase-1 (PDK1) activation were not affected by treatments, as shown by the lack of changes in phospho-EGFR (tyr 1045) and phospho-PDK1 (ser 241) levels ( Figures 2c and d) , indicating that the peptide acts downstream of Akt activation, consistent with PP2A activation. Akt exerts its signal to proliferate by phosphorylating protein substrates such as mammalian target of rapamycin (mTOR) and glycogen synthase kinase 3 beta (GSK-3b). To examine the effects of COG112 on Akt signaling partners in U87 cells, mTOR activation and GSK-3b inhibition were measured by western blot analysis. The EGF stimulation caused a marked increase in mTOR serine-2448 phosphorylation in both cell lines tested ( Figure 3a ). However, COG112 pre-incubation decreased mTOR activation with a threshold concentration 410 nM. In OA-treated cells, mTOR phosphorylation is not decreased with respect to COG112 concentration. Similarly, GSK-3b serine-9 phosphorylation was increased upon EGF stimulation, which was Figure 2 COG112 inhibits Akt activation through PP2A. Serumstarved MDA-MB-231 cells were exposed to COG112 for 2 h and stimulated with EGF. (a) Western blot analysis of Akt activation in response to COG112 and EGF in the presence or absence of OA. (b) COG112 inhibits Akt activation in a concentration-and OAdependent manner. Densitometry analysis of Akt (ser-473) phosphorylation versus COG112 is shown ± OA. Data represent mean ± s.e.m. and significance (*Po0.05) was determined by paired t-test. (c) Representative western blot and (d) densitometry analysis of EGFR and PDK1 activation in response to COG112 and EGF. Data represent mean values (±s.e.m.) of the relative densitometry of phospho-protein:total protein from three independent experiments. Significance (*Po0.05) is relative to EGF controls. c-Myc is also a substrate for, and is negatively regulated by, PP2A activity Sears, 2006,2008) . To determine the activity of PP2A on this endogenous protein substrate in response to COG112, MDA-MB-231 cells were treated as above. Total c-Myc protein levels were measured by western blot analysis and normalized to actin (Figure 3c ). COG112 caused a concentration-dependent decrease in c-Myc protein levels in the absence, but not in the presence of OA, indicating that the decrease in c-Myc protein levels by COG112 is mediated by PP2A. To further assess the ability of COG112 to inhibit c-Myc transcriptional activity, nuclear fractions were isolated from COG112treated cells and the ability of c-Myc to bind its consensus DNA sequence was measured by an ELISA-based kit. COG112 caused a concentration-dependent decrease in the amount of c-Myc able to bind DNA (Figure 3d ).
Because COG112 inhibited Akt activation and its downstream signaling, we examined the effects of COG112 on cellular proliferation. Adherent MDA-MB-231, U87 and Detroit 551 human fibroblast cells were grown for 24 h in the presence of COG112 and cellular proliferation was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. Serum stimulation approximately doubled the number of cells compared with serum-starved control cells (Figure 3e ). In MDA-MB-231 and U87 cells, COG112 caused a significant decrease in proliferation at 100 and 1000 nM. However, COG112 did not affect the human fibroblast cell line, indicating that this potential agent is innocuous to non-cancerous cells.
COG112 dissociates nm23-H1 from SET
To determine whether COG112 can displace nm23-H1 from its inhibitory complex with SET, MDA-MB-231 cells were treated with COG112 for 3 h. Western blot of input lysate shows equal amounts of both SET and nm23-H1 in treated cells (Figure 4a ). Co-immunoprecipitation studies show that SET is bound to nm23-H1 in untreated control cells; however, COG112 caused a significant decrease in nm23-H1 bound to SET (Figures 4a and b ). COG112 treatment for 3 h also resulted in the increased nuclear localization of nm23-H1, as determined by western blot analysis of fractionated cells (Figure 4c ). To observe the localization of nm23-H1 with respect to time of COG112 administration, MDA-MB-231 cells were treated with 1 mM COG112 for various times. Western blotting of fractionated cells shows a marked increase in nuclear nm23-H1 after 3 and 18 h of COG112 treatment. To examine the effect of COG112 on nm23-H1 exonuclease activity, MDA-MB-231 cells were incubated with COG112 and nuclear fractions were isolated. The exonuclease activity of the nuclear extract was assessed by S1 nucleasehypersensitive site oligonucleotide digestion (Ma et al., 2002) . COG112 caused a marked increase in exonuclease activity (Figure 4e ), corresponding to increased nm23-H1 nuclear translocation.
COG112 inhibits SET association with Rac1, cell migration and invasion SET association is necessary for Rac1-mediated cell migration (ten Klooster et al., 2007) . To determine whether COG112 can inhibit SET/Rac1 association, serum-starved MDA-MB-231 cells were incubated with COG112 for 3 h and then stimulated with EGF for 30 min. Co-immunoprecipitation experiments show that Rac1 complexes to SET in EGF-stimulated cells, but not in serum-starved cells (Figure 5a ). Pre-treating cells with COG112 before EGF stimulation caused a concentration-dependent decrease in Rac1's association with SET. To measure the effect of COG112 on Rac1-GTPase activity, cells were treated as above and active Rac1 was pulled down with a GST-PAK1 p21-binding domain fusion protein. Western blot shows that COG112 caused a concentration-dependent decrease in active Rac1-GTPase consistent with decreased SET/ Rac1 binding (Figure 5b ). The effect of COG112 on cell migration and invasion was assessed in MDA-MB-231 cells. Using 5% fetal bovine serum as a chemotractant, MDA-MB-231 cells were incubated with COG112 and allowed to migrate or invade for 24 h. COG112 treatment (X10 nM) significantly decreased cell migration compared with vehicle-treated control cells (Figure 5c ). At 1 mM COG112, migration was almost completely inhibited. Furthermore, cell invasion through matrigel correlated with the cell migration data, showing that treatment with X10 nM COG112 significantly decreased invasion compared with vehicletreated control cells, and invasion was almost completely inhibited at 1 mM COG112 (Figure 5d ).
Discussion
This study demonstrates that targeting SET, an oncoprotein with numerous cellular functions, has multiple (d) MDA-MB-231 cells were treated with COG112 (1 mM) for the indicated times and nm23-H1 levels were determined from fractionated cells. (e) COG112 increased the nuclear exonuclease activity of MDA-MB-231 cells. S1 nuclease-hypersensitive site oligonucleotides were incubated with nuclear protein from treated cells; DNA cleavage products are shown from a representative experiment.
Functional inhibition of SET oncoprotein CH Switzer et al effects in human cancer cell lines. COG112, a chimeric peptide consisting of a short antennapedia sequence fused to the receptor recognition sequence of ApoE, was recently shown to increase PP2A activity in murine microglia cells by interacting with SET (Christensen et al., 2011) . Here we demonstrate that COG112 directly interacts with SET protein from MDA-MB-231 breast cancer cells, confirming that the peptide interacts with SET regardless of cell type. Furthermore, whole-cell experiments show that the interaction between COG112 and SET inhibited the formation of the SET/PP2A-c complex in EGF-stimulated cells (Figure 1b ). COG112mediated inhibition of Set also correlated with increased cellular PP2A activity levels. COG112 (X10 nM) pretreatment resulted in a significant increase in PP2A phosphatase activity compared with EGF-treated controls (Figure 1c ), but did not completely restore PP2A activity levels to those found in controls. These results suggest that PP2A is negatively regulated by additional factors beyond SET in EGF-stimulated cancer cells. One of these factors may be Jak2, as EGFR activation induces Jak2 signaling (Olayioye et al., 1999) , which has recently been shown to increase SET expression (Samanta et al., 2009 ). Furthermore, Jak2 inhibition caused an increase in PP2A activity, suggesting a role for Jak2 in SET/PP2A regulation (Samanta et al., 2009) . Other protein inhibitors of PP2A have been described, such as cancerous inhibitor PP2A (CIP2A) (Junttila et al., 2007) and I 1 PP2A (Li et al., 1995) , and chemical factors such as reactive oxygen species may also contribute to the inhibition or negative regulation of PP2A activity (Sommer et al., 2002; Kim et al., 2003) . Protein phosphatase 2A has tumor suppressor functions and therefore its activity in cancer cells is commonly decreased by multiple mechanisms (Westermarck and Hahn, 2008 ). An attractive approach to cancer therapy is to pharmacologically increase PP2A activity, as PP2A negatively regulates many signaling pathways associated with cancer progression and metastasis, such as p38, Akt, b-catenin and c-Myc. Although PP2A is involved in many processes and recognizes a variety of substrates, PP2A is a highly regulated enzyme complex that comprises three subunits: a catalytic subunit, a scaffolding subunit and a regulatory subunit (Eichhorn et al., 2009 ). PP2A-specific activity, substrate affinity and cellular localization are determined by the holoenzyme's subunit composition. Although releasing PP2A-c from its inhibitory complex with SET does not affect the formation of subsequent PP2A complexes, it does represent a strategy resulting in an overall increase in PP2A activity. Thus, we cannot conclude that specific PP2A-heterotrimeric complexes are promoted by COG112, but rather that the levels of active PP2A heterotrimers, which are free of associated SET, are increased by COG112.
COG112 resulted in decreased Akt, mTOR and GSK-3b phosphorylation in response to EGF. Akt and its downstream substrates, mTOR and GSK-3b, are regulated by PP2A (Westermarck and Hahn, 2008) . However, in the presence of OA, COG112 did not affect Akt, mTOR or GSK-3b activation, indicating that PP2A Functional inhibition of SET oncoprotein CH Switzer et al mediated the inhibition of Akt signaling. Additionally, c-Myc is regulated by PP2A activity (Arnold and Sears, 2006) and COG112 caused c-Myc protein and DNA binding to decrease in an OA-sensitive manner. Additionally, these data suggest that PP2A activation results in decreased cancer cell proliferation, which is consistent with previous studies on pharmacological activation of PP2A in leukemias Neviani, 2006, 2008; Neviani et al., 2007) . These results strongly support a mechanism whereby COG112 increases PP2A activity, and that this increased phosphatase activity decreased Akt signaling and c-Myc protein levels.
The SET oncoprotein functions to inhibit the metastasis suppressor protein, nm23-H1, by sequestering it in the cytosol (Fan et al., 2003) . We show that COG112 treatment resulted in the decreased association of nm23-H1 with its inhibitor SET (Figures 4a and b) , together with a concomitant increase in nuclear accumulation of nm23-H1 (Figures 4c and d) . The metastasis suppressor nm23-H1 is a multi-functional protein; however, its DNA 3 0 -5 0 exonuclease activity is important to its metastasis suppressor function (Zhang et al., 2010) . Furthermore, we show that COG112 increased the nuclear exonuclease activity of nm23-H1 (Figure 4e ). SET is a substrate for Granzyme A, and upon cytotoxic T-lymphocyte attack Granzyme A cleaves SET, which then allows nm23-H1 to exert its exonuclease activity (Fan et al., 2003) . Our results indicate that COG112 may serve as an anti-metastasis agent for primary tumors through a mechanism whereby nm23-H1 exonuclease function is increased when COG112-SET complexes are increased. Cancer cells escape the immune response predominantly through immunosuppression (Stewart and Abrams, 2008) ; so an agent such as COG112 that can mimic cytotoxic-T lymphocyte attack in the absence of a natural immune assault may have beneficial clinical impact. nm23-H1 expression is pharmacologically increased by medroxyprogesterone (Ouatas et al., 2003) that reduces metastases in vivo (Palmieri et al., 2005) , and we hypothesize that COG112 may increase the efficacy of medroxyprogesterone even further by inhibiting the naturally occurring SET inhibitor of nm23-H1 metastasis suppressor activity.
SET also contributes to tumor metastasis by binding to Rac1 during cell migration (ten Klooster et al., 2007) . Cellular migration is necessary for cancer metastasis, as individual cancer cells must actively move to distal sites. COG112 inhibited the formation of Rac1 complexes with SET as well as active Rac1-GTPase in EGFstimulated MDA-MB-231 cells. Preventing the Rac1-SET complex formation resulted in the inhibition of migration and invasion in COG112-treated cells. In addition to affecting migration by inhibiting the Rac1-SET complex formation and Rac1 activation, COG112 may also inhibit migration by other mechanisms. For example, the activation of Rac1 initiates signaling through PAK1 and p38 mitogen-activated protein kinase (MAPK) (Zhang et al., 1995) and PP2A is known to suppress p38 and PAK1 activation (Westphal et al., 1999; Sundaresan and Farndale, 2002) . Akt signaling is also known to contribute to migration (Qiao et al., 2008) , and this is another mechanism by which COG112 may stimulate PP2A activity to inhibit migration. Also, nm23-H1 reduces Rac1 activity by interacting with the Rac1specific nucleotide exchange factor, Tiam1 (Otsuki et al., 2001) . The potential for COG112 to simultaneously affect Rac1 function through PP2A and nm23-H1 activation highlights the multi-pathway approach of SET inhibition.
The remarkable success in developing agents that target specific pathways has advanced our understanding of the molecular mechanisms that cause cancer. Even with this success, the clinical reality is that cancer persists and even recurs within the same patient because of tumor heterogeneity that leads to an attenuated response to an individual anti-cancer therapy. Thus, it is necessary to develop agents that do not target just one pathway, but, instead, concurrently target several cancer pathways without toxicity toward healthy tissues (Zhu et al., 2008) . COG112 showed selective proliferation inhibition for aggressive cancer cells but did not affect normal fibroblasts (Figure 3e ), suggesting that COG112 may fulfill these ideal requirements. The multi-functional role of COG112 exerted through the inhibition of SET indicates that SET may be a versatile molecular target because of its involvement with numerous tumorand metastasis-promoting functions (Figure 6 ). Furthermore, the tumor suppressor PP2A is emerging as a target with inhibitory activity toward multiple cellular signaling pathways that are critical to proliferation, metastasis and angiogenesis in cancer maturation (Eichhorn et al., 2009) . We propose that targeting the oncoprotein SET, an inhibitor of PP2A and other Figure 6 Targeting SET oncoprotein function has multiple effects: an overview scheme of COG112 inhibition of SET functions. (a) SET functions to inhibit both PP2A and nm23-H1. SET is also required for Rac1-mediated cell migration. (b) In the presence of COG112, SET is unable to form protein complexes with PP2A-c, nm23-H1 and Rac1. We conclude that COG112 inhibits multiple oncoprotein functions of SET in human cancer cell lines. anticancer proteins, is a novel strategy for simultaneously affecting multiple pathways that are implicated in cancer progression and metastasis.
We conclude that a novel ApoE-based peptide, COG112, inhibits the ability of SET to associate with PP2A-c, which correlates with increased PP2A activity in EGF-stimulated cancer cells ( Figure 6 ). Furthermore, COG112 inhibited Akt and c-Myc activity by a mechanism including increasing PP2A activity. We also conclude that COG112 releases SET from nm23-H1, resulting in increased metastasis suppressor function of nm23-H1. Finally, we conclude that COG112 inhibits cancer cell migration and invasion by inhibiting the binding of SET to Rac1. These conclusions point to the need for PP2A activators and/or Akt inhibitors and to the desire to pharmacologically activate the tumor suppressor nm23-H1, as a combinatorial approach to control cancer. These results demonstrate that targeting SET oncoprotein functions is a novel approach to cancer therapy that can help achieve these goals.
Materials and methods
Cell culture and reagents U87-MG (U87) human glioblastoma, MDA-MB-231 human breast adenocarcinoma cells and Detroit 551 human skin fibroblasts (American Type Culture Collection, Manassas, VA, USA) were cultured in Dulbecco's modified Eagle's medium, RPMI medium and minimum essential medium, respectively (Invitrogen, Carlsbad, CA, USA), containing 10% fetal bovine serum (Atlanta Biologicals, Norcross, GA, USA), 100 IU/ml penicillin and 100 mg/ml streptomycin (Sigma-Aldrich, St Louis, MO, USA) and passaged two to three times per week. Human recombinant EGF was purchased from R&D Systems (Minneapolis, MN, USA). Okadaic acid was purchased from Millipore (Billerica, MA, USA). Pan Akt, p-Akt (serine 473), p-EGFR (tyrosine 992), EGFR, p-mTOR (serine 2448), total mTOR, p-GSK-3b, total GSK-3b, c-Myc, p-PDK1 (ser-2421), PDK1, lamin A, anti-mouse and antirabbit horse radish peroxidase antibodies were purchased from Cell Signaling (Danvers, MA, USA), Rac1 antibody was from BD Biosciences (San Jose, CA, USA) and SET/I 2 PP2A, PP2Ac, nm23-H1, a-tubulin and actin antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Peptide synthesis
COG112 is a chimeric peptide containing the antennapedia protein transduction domain (RQIKIWFQNRRMKWKKC) followed by COG133 (LRVRLASHLRKLRKRLL) (Laskowitz et al., 2001) . The resulting sequence of COG112 (acetyl-RQ IKIWFQNRRMKWKKCLRVRLASHLRKLRKRLL-amide) (Li et al., 2006) was synthesized using standard fluorenylmethyloxycarbonyl chloride (Fmoc) chemistries and purified by NeoMPS (San Diego, CA, USA). Biotin was added at the amino-terminus during synthesis to produce biotin-COG112 (Polypeptide Systems, San Diego, CA, USA). Lyophilized peptides were resuspended in sterile phosphate-buffered saline and stock solutions were stored at À20 1C.
Immunoprecipitation and western blot identification of SETCOG112 complexes MDA-MB-231 cells were grown to log phase and lysates prepared in NP40 buffer (100 mM Tris, 0.2% NP40, 150 mM NaCl, pH 7.4). Protein concentrations of the lysate were adjusted to 1 mg of total protein per ml of solution. Streptavidin agarose beads (1 ml) were washed with 10 ml of NP40 buffer and 0.1 ml of beads added to 2 ml of total protein extract (2 mg). After incubation for 1 h at 4 1C, beads were collected by centrifugation and the cleared lysate was removed and split into two tubes. Biotin-COG112 (10 mg) was added to one tube and biotin (1 mg) added to the other as a negative control. After incubation at 2 h at 4 1C, 50 ml of washed beads was added to the lysate/peptide mixtures and incubated for an additional 2 h. Beads were collected by centrifugation, washed 5 Â with chilled NP40 buffer and centrifugation cycles. A volume of 15 ml of 4 Â lithium dodecyl sulfate sample buffer (Invitrogen) was added to the beads and then heated to 90 1C for 10 min and briefly centrifuged. Supernatant proteins were analyzed by western blot as detailed below.
Western blot analysis
Serum-starved cells were treated for 2 h with COG112 and stimulated with EGF for 5 min at 37 1C. The cells were placed on ice and the media was aspirated and the cells were washed with cold phosphate saline buffer. Cells were harvested in cold 2 Â RIPA lysis buffer supplemented with 1 mM Na 2 VO 4 , 1 mM NaF, Protease Inhibitor Cocktail Set I (EMD Chemicals, Gibbstown, NJ, USA) and 0.2 mM phenylmethylsulfonyl fluoride (Sigma-Aldrich) and stored at À80 1C. The whole-cell lysates were cleared and the protein content was determined by bicinchoninic assay (BCA assay, Thermo Scientific, Rockford, IL, USA). Nuclear protein extracts were isolated using a commercial kit (Active Motif, Carlsbad, CA, USA). Western blotting was performed as previously described (Switzer et al., 2009) . Polyvinylidene fluoride membranes were imaged using ECF Western blotting kit (GE Healthcare, Piscataway, NJ, USA) and recorded on a FluoroChem SP imaging system using AlphaEase FC software (Alpha Innotech, San Leandro, CA, USA). Images were further analyzed using ImageQuant software (Molecular Dynamics, Sunnyvale, CA, USA).
Co-immunoprecipitation experiments and active Rac1-GTPase pull-down
Serum-starved MDA-MB-231 or U87 cells were incubated with COG112 for 2 h before EGF stimulation for 30 min. Cells were lysed as above and Rac1 protein complexes were immunoprecipitated using Dynabeads Protein G (Invitrogen) conjugated with either anti-Rac1 or anti-SET. Isolated protein complexes were washed with phosphate buffer saline (3 Â ) and analyzed for both Rac1 and SET by western blot, as described above. Active Rac1-GTPase was measured using a commercially available kit as directed (Active Rac1 Pull-Down and Detection Kit, Thermo Scientific).
Phosphatase activity assay
Serum-starved MDA-MB-231 or U87 cells were treated with COG112 for 2 h and then stimulated with EGF (100 ng/ml) for 5 min. Cells were lysed with NP40 buffer supplemented with 1 mM Na 2 VO 4 , 1 mM NaF, Protease Inhibitor Cocktail Set I (EMD Chemicals, NJ, USA) and 0.2 mM phenylmethylsulfonyl fluoride (Sigma-Aldrich), and stored at À80 1C. PP2A phosphatase activity was measured as previously described (Switzer et al., 2009) . Briefly, immunopreciptated PP2A-c is incubated with a PP2A-specific phospho-peptide substrate Arg-Arg-Ala-pThr-Val-Ala (BIOMOL, Plymouth Meeting, PA, USA) for 30 min at 30 1C. The amount of phosphate released is determined using the Malachite green assay (Echelon Bioscience, Salt Lake City, UT, USA).
c-Myc activation assay
The c-Myc activation was examined using the TransAM c-Myc ELISA (Active Motif). Briefly, nuclear protein extracts were allowed to bind to a c-Myc consensus sequence. Wells were washed three times and c-Myc antibody was added to each well for 1 h. Wells were washed three times and incubated for 1 h with horseradish peroxidase-conjugated antibody. Wells were washed four times before developing solution (100 ml) was added to each well and incubated for 10 min. Stop solution was added and absorbance measured at 450 nm.
Proliferation assays
Cells were seeded in media containing 10% fetal bovine serum and incubated for 6 h to allow the cells to adhere. The cells are washed (3 Â ) with serum-free media and serum-starved overnight. The cells were then incubated for 24 h in serumreplete media containing the indicated concentration of COG112. Proliferation was determined by the MTT assay and the data represent six replicate experiments.
Exonuclease assay
The metastasis suppressor nm23-H1 exonuclease activity was assessed, as previously described, with modification (Ma et al., 2002) . Subconfluent MDA-MB-231 or U87 cells were treated with COG112 for 6 h in serum-containing media and nuclear extracts were isolated as above. Single-stranded 5 0 -Alexa Fluor 488-labeled S1 nuclease-hypersensitive site oligonucleotides (Invitrogen) were incubated with 5 mg of nuclear protein in Tris-buffered saline, supplemented with 2 mM MgCl 2 for 2 h at room temperature. DNA cleavage products were separated by electrophoresis through 2% polyacrylamide gels and visualized by UV-fluorescent imaging using a FluoroChem SP system from Alpha Innotech. The S1 nuclease-hypersensitive site anti-sense sequence used was 3 0 -AGAGAGGTGGAGGGGGGGT GGGGAGGTGTGTAG-5 0 .
Cell migration and invasion assays MDA-MB-231 cells (5000 cells in 0.5 ml serum-free Roswell Park Memorial Institute medium with indicated concentration of COG112) were placed into either BD multiwell insert systems (for migration assays) or BD matrigel invasion chambers (for invasion assays) and 0.75 ml of RPMI medium þ 5% fetal bovine serum was added to the bottom chamber. Cells were incubated for 24 h at 37 1C; nonmigrating/invading cells were removed by aspiration and membranes were scrubbed with wet cotton swabs. Migrating/ invading cells were then fixed in cold methanol for 10 min at À20 1C, rinsed with water, stained with crystal violet, rinsed again and dried. The cells were then manually counted under Â 40 magnification to determine the number of migrating or invading cells.
Statistical analysis
Data represented are the means of at least three independent experiments±s.e.m. Statistical comparisons were performed by t-test or one-way ANOVA with Dunnett's post-test analysis using GraphPad Prism software (La Jolla, CA, USA). Significance was indicated by Po0.05.
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